1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030

Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030

  • September 2021
  • 175 pages
  • ID: 6151672
  • Format: PDF
  • The Business Research Company

Summary

Table of Contents

Major players in the Alzheimer’s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd.

The global alzheimer’s disease treatment market is expected to grow from $3.43 billion in 2020 to $3.76 billion in 2021 at a compound annual growth rate (CAGR) of 9.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $5.91 billion in 2025 at a CAGR of 12%.

The global Alzheimer’s disease treatment market consists of sales of drugs used to treat Alzheimer’s disease.Alzheimer’s disease is a progressive neurological disorder causing degeneration of brain cells, resulting in dementia (a condition that causes a decline in thinking, behavioural and social skills).

The progression of this disease causes severe memory impairment and the person may lose the ability to carry out everyday tasks.

The Alzheimer’s disease treatment market covered in this report is segmented by drug class into cholinergic, memantine, combined drug, AChE inhibitors, immunoglobulins and by drug type into cholinesterase inhibitors, NMDA receptor antagonists.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Lack of techniques for diagnosing Alzheimer’s disease (AD) is expected to limit the growth of the global Alzheimer’s disease treatment market.There is no definitive blood test, brain scan, or physical exam to diagnose AD, and so many conditions can produce symptoms like dementia, which is the primary clinical symptom of AD, making the diagnosis complicated.

The lack of a single test for diagnosis, specialists such as neurologists, neuropsychologists, geriatricians and geriatric psychiatrists use a variety of approaches for diagnosis to confirm dementia, but it is still difficult to find the cause resulting in late diagnosis. Lack of proper and quick diagnosis for AD hampers the market growth as it leads to a reduced number of diagnosed cases and thereby reduces the consumption of AD drugs.

In January 2020, Biogen Inc., an American multinational biotechnology company, acquired Pfizer Inc. for an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments. Through this acquisition, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD). Pfizer Inc. is an American multinational pharmaceutical corporation engaged in the discovery, development and manufacture of healthcare products including medicines and vaccines.

The increasing cases of Alzheimer’s is a major factor contributing to the growth of the Alzheimer’s treatment market.Alzheimer’s is the most common type of dementia.

The USA Alzheimer’s Association expects that all the states in the US are projected to face a rise of at least 14% in the number of Alzheimer’s people between 2017 and 2025 due to the increase in the geriatric population.At the global level, the estimated new cases of Alzheimer’s is expected to grow by 35% to 615,000 by 2030, and by 110% to 959,000 by 2050.

Therefore, the increasing prevalence of Alzheimer’s disease is expected to drive the growth of the global Alzheimer’s disease treatment market.

Increasing R&D investments and collaborations due to the emerging technologies for the treatment is a key trend in Alzheimer’s disease (AD) treatment market.The Alzheimer’s Association is assisting with funds to researchers in search of innovative therapeutic approaches and seeks more government funding for Alzheimer’s studies.

Technologies such as ?-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are emerging in the AD market.For instance, Comentis and Astellas collaborated and entered the BACE inhibitor field on their peptidomimetic series.

Manufacturing companies such as AC Immune, Adamas Pharmaceuticals, INmune Bio, Intra-Cellular Therapies, vTv Therapeutics are more focused on R&D investments with their research molecules in the clinical trials to achieve a breakthrough for the treatment of AD.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on